Total Payments
$9,486
2024 Payments
$426.99
Companies
24
Transactions
125
Medicare Patients
4,197
Medicare Billing
$4.4M
Payment Breakdown by Category
Research$5,523 (58.2%)
Food & Beverage$3,233 (34.1%)
Travel$708.05 (7.5%)
Education$21.72 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,523 | 13 | 58.2% |
| Food and Beverage | $3,233 | 107 | 34.1% |
| Travel and Lodging | $708.05 | 3 | 7.5% |
| Education | $21.72 | 2 | 0.2% |
Payments by Type
Research
$5,523
13 transactions
General
$3,963
112 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Karyopharm Therapeutics Inc. | $3,200 | 1 | $0 (2022) |
| TESARO, Inc. | $1,540 | 13 | $0 (2018) |
| Clovis Oncology, Inc. | $1,170 | 19 | $0 (2022) |
| F. Hoffmann-La Roche AG | $1,057 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $555.40 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $442.13 | 14 | $0 (2024) |
| Eisai Inc. | $354.90 | 16 | $0 (2024) |
| Intuitive Surgical, Inc. | $251.18 | 4 | $0 (2023) |
| Russell Health, Inc. | $209.28 | 1 | $0 (2018) |
| Seagen Inc. | $176.65 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $426.99 | 18 | Merck Sharp & Dohme LLC ($142.27) |
| 2023 | $698.11 | 22 | Intuitive Surgical, Inc. ($197.52) |
| 2022 | $3,633 | 18 | Karyopharm Therapeutics Inc. ($3,200) |
| 2021 | $1,419 | 21 | F. Hoffmann-La Roche AG ($1,057) |
| 2020 | $126.97 | 7 | Merck Sharp & Dohme Corporation ($35.03) |
| 2019 | $300.24 | 10 | AstraZeneca Pharmaceuticals LP ($159.23) |
| 2018 | $1,412 | 14 | Clovis Oncology, Inc. ($952.78) |
| 2017 | $1,470 | 15 | TESARO, Inc. ($1,423) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/27/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Oncology | ||||||
| 06/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $32.21 | General |
| Category: Oncology | ||||||
| 06/06/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Oncology | ||||||
| 05/01/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Oncology | ||||||
| 04/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $34.01 | General |
| Category: Oncology | ||||||
| 03/28/2024 | Pacira Pharmaceuticals Incorporated | Exparel (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Pain Management | ||||||
| 03/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: Oncology | ||||||
| 03/07/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Oncology | ||||||
| 02/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2024 | ImmunoGen, Inc. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $34.51 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Oncology | ||||||
| 12/21/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 11/30/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2023 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $26.50 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.65 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.85 | General |
| Category: Oncology | ||||||
| 09/28/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | Karyopharm Therapeutics Inc. | $3,200 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $1,266 | 10 |
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $1,057 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 851 | 54,406 | $2.4M | $1.1M |
| 2022 | 24 | 944 | 59,398 | $2.2M | $858,603 |
| 2021 | 25 | 1,030 | 61,618 | $2.4M | $1.1M |
| 2020 | 32 | 1,372 | 89,874 | $3.4M | $1.4M |
Total Patients
4,197
Total Services
265,296
Medicare Billing
$4.4M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 18 | 15,482 | $1.5M | $876,875 | 56.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 198 | 559 | $109,005 | $53,278 | 48.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 358 | $137,830 | $38,896 | 28.2% |
| 58548 | Removal of uterus, cervix, and lymph nodes of pelvis with biopsy of aortic lymph node using an endoscope | Facility | 2023 | 17 | 17 | $93,500 | $26,587 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 78 | 78 | $30,810 | $13,778 | 44.7% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 14 | 14 | $49,000 | $10,736 | 21.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 28 | 429 | $64,350 | $10,037 | 15.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 142 | $35,500 | $7,675 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 50 | $6,750 | $3,661 | 54.2% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 31 | 209 | $25,160 | $3,436 | 13.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 47 | 184 | $10,120 | $3,367 | 33.3% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 24 | 30,666 | $122,664 | $3,108 | 2.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 39 | 374 | $11,220 | $2,846 | 25.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 29 | 117 | $21,060 | $2,807 | 13.3% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 26 | 1,272 | $111,250 | $2,533 | 2.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 17 | $5,950 | $2,424 | 40.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 63 | 149 | $2,980 | $1,244 | 41.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 38 | $13,300 | $1,003 | 7.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 30 | 2,998 | $8,994 | $293.52 | 3.3% |
| 38792 | Injection of radioactive material for x-ray identification of lymph node | Facility | 2023 | 13 | 13 | $3,250 | $176.02 | 5.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 28 | 183 | $417.24 | $152.57 | 36.6% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 27 | 990 | $8,880 | $75.92 | 0.9% |
| J3490 | Unclassified drugs | Office | 2023 | 13 | 67 | $5,025 | $40.22 | 0.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 19 | 11,780 | $1.2M | $642,510 | 54.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 632 | $123,440 | $60,153 | 48.7% |
About Dr. Sudarshan Sharma, MD
Dr. Sudarshan Sharma, MD is a Gynecology healthcare provider based in Hinsdale, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1740265974.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sudarshan Sharma, MD has received a total of $9,486 in payments from pharmaceutical and medical device companies, with $426.99 received in 2024. These payments were reported across 125 transactions from 24 companies. The most common payment nature is "" ($5,523).
As a Medicare-enrolled provider, Sharma has provided services to 4,197 Medicare beneficiaries, totaling 265,296 services with total Medicare billing of $4.4M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecology
- Other Specialties Gynecologic Oncology
- Location Hinsdale, IL
- Active Since 12/09/2005
- Last Updated 06/04/2024
- Taxonomy Code 207VG0400X
- Entity Type Individual
- NPI Number 1740265974
Products in Payments
- XPOVIO (Drug) $3,200
- ZEJULA (Drug) $1,628
- Rubraca (Drug) $1,097
- TECENTRIQ (Biological) $1,057
- KEYTRUDA (Biological) $465.86
- LYNPARZA (Drug) $442.13
- Lenvima (Drug) $354.90
- Da Vinci Surgical System (Device) $251.18
- PalinGen Flow (Biological) $209.28
- TIVDAK (Biological) $184.12
- Phesgo (Biological) $104.18
- AirSeal (Device) $76.92
- LYNPARZA (Biological) $46.55
- SANCUSO (Drug) $34.38
- ELAHERE (Drug) $34.20
- VEGZELMA (Biological) $31.47
- AVASTIN (Drug) $26.50
- Exparel (Drug) $21.30
- YONDELIS (Drug) $19.28
- FLEXITOUCH (Device) $18.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.